Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study

Declaration of Competing Interest AG, AMM, ASSP, AXA, BFFR, CML, FCS, JFSF, LCLL, LRG, TBT, JICFN: declared no conflict of interest. ACMS, ALB, CAK, DDGH, EKEAL, EMR, MCSR, MK, RCFB: received funds or reimbursement from BioMarin Brasil Farmaceutica LTDA for attending related symposia, or speaker hon...

Full description

Bibliographic Details
Authors: Horovitz, Dafne Dain Gandelman, Leão, Emília Katiane Embiruçu de Araújo, Ribeiro, Erlane M., Martins, Ana M., Barth, Anneliese Lopes, Neri, João I. C. F., Kerstenetzky, Marcelo, Siqueira, Ana C. M., Ribeiro, Bethania F. R., Kim, Chong A., Santos, Francisca C., Franco, José F. S., Lichtvan, Leniza C. L., Giuliani, Liane R., Rodrigues, Maria do C. S., Bonatti, Renata C. F., Teixeira, Thaís B., Gonçalves, Alexandra, Lourenço, Charles M., Pereira, Ane S. S., Acosta, Angelina X.
Format: article
Status:Published version
Publication Date:2021
Country:Brasil
Institution:Fundação Oswaldo Cruz (FIOCRUZ)
Repository:Repositório Institucional da FIOCRUZ (ARCA)
Language:English
OAI Identifier:oai:arca.fiocruz.br:icict/46480
Online Access:https://arca.fiocruz.br/handle/icict/46480
Access Level:Open access
Keyword:Enzyme replacement therapy
Galsulfase
Long-term follow-up
Lysosomal storage disorder
MPS VI
Mucopolysaccharidosis VI
Maroteaux-Lamy Syndrome
Description
Summary:Declaration of Competing Interest AG, AMM, ASSP, AXA, BFFR, CML, FCS, JFSF, LCLL, LRG, TBT, JICFN: declared no conflict of interest. ACMS, ALB, CAK, DDGH, EKEAL, EMR, MCSR, MK, RCFB: received funds or reimbursement from BioMarin Brasil Farmaceutica LTDA for attending related symposia, or speaker honoraria. DDGH: received consulting fees from BioMarin Brasil Farmaceutica LTDA.

Similar Items